{"id":4037,"date":"2025-03-31T18:11:56","date_gmt":"2025-03-31T18:11:56","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/ganciclovir-txt\/"},"modified":"2025-03-31T18:11:56","modified_gmt":"2025-03-31T18:11:56","slug":"ganciclovir-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/ganciclovir-txt\/","title":{"rendered":"Ganciclovir.txt"},"content":{"rendered":"

Ganciclovir <\/h1>\n

CLINICAL USE <\/H3>
\nAntiviral agent :Treatment of life- or sight-threatening cytomegalovirus (CMV) in immunocompromised peopleCMV prophylaxis in immunosuppressed patients secondary to organ transplantation

DOSE IN NORMAL RENAL FUNCTION <\/H3>Induction\/treatment of active CMV disease: 5 mg\/kg 12 hourly for 14\u201321 daysMaintenance for CMV retinitis: 6 mg\/kg per day for 5 days per week or 5 mg\/kg daily until recovery of adequate immunity

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :255.2<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :<2<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 84.6\u201394.6<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.54\u20130.87<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :2.9\/28.5

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : See \u2018Other Information\u2019
  • 10 to 20 &nbsp &nbsp : See \u2018Other Information\u2019
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : See \u2018Other Information\u2019

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Dialysed. 1.25 mg\/kg every day<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. 1.25 mg\/kg every day, given post dialysis on dialysis days
  • HDF\/high flux &nbsp :Dialysed. 1.25 mg\/kg every day, given post dialysis on dialysis days
  • CAV\/VVHD &nbsp &nbsp &nbsp:Dialysed. 2.5 mg\/kg per day

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Antibacterials: increased risk of convulsions with imipenem-cilastatin\n
  • Antivirals: possibly increased didanosine concentration; avoid with lamivudine; profound myelosuppression with zidovudine \u2013 avoid if possibleIncreased risk of myelosuppression with other myelosuppressive drugsMycophenolate: concomitant treatment with ganciclovir and mycophenolate increase plasma levels of both drugs

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>Reconstitute 1 vial (500 mg) with 10 mL water for injection (50 mg\/mL), then transfer dose to 100 mL sodium chloride 0.9%

    Route <\/H4>IV peripherally in fast-flowing vein or centrally \u2013 see below

    Rate of Administration <\/H4>Over 1 hour

    Comments<\/H4>May give 50% dose over 15 minutes after\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : in washback (unlicensed)

    OTHER INFORMATION <\/H4>From SPC:Creatinine Clearance Dose (mL\/min) (mg\/kg\/hours) >70 5 mg\/kg 12 hourly 50 69 2.5 mg\/kg 12 hourly 25 49 2.5 mg\/kg 24 hourly 10 24 1.25 mg\/kg 24 hourly
  • 50 5 mg\/kg 12 hourly 25 50 2.5 mg\/kg 12 hourly 10 25 2.5 mg\/kg 24 hourly
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : 1.25 mg\/kg 24 hourlyMonitor patient for myelosuppression, particularly in patients receiving prophylactic co-trimoxazole therapyPre-dialysis therapeutic blood levels in range 5\u201312 mg\/LNot to be infused in concentrations over 10 mg\/mL peripherally
    \n","protected":false},"excerpt":{"rendered":"

    Ganciclovir CLINICAL USE Antiviral agent :Treatment of life- or sight-threatening<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4037","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4037","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4037"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4037\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4037"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4037"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4037"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}